Ocular Therapeutix (OCUL) Research & Development: 2013-2025
Historic Research & Development for Ocular Therapeutix (OCUL) over the last 13 years, with Sep 2025 value amounting to $52.4 million.
- Ocular Therapeutix's Research & Development rose 41.30% to $52.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $187.3 million, marking a year-over-year increase of 82.11%. This contributed to the annual value of $127.6 million for FY2024, which is 109.05% up from last year.
- Per Ocular Therapeutix's latest filing, its Research & Development stood at $52.4 million for Q3 2025, which was up 2.50% from $51.1 million recorded in Q2 2025.
- In the past 5 years, Ocular Therapeutix's Research & Development ranged from a high of $52.4 million in Q3 2025 and a low of $10.9 million during Q1 2021.
- Over the past 3 years, Ocular Therapeutix's median Research & Development value was $28.9 million (recorded in 2024), while the average stood at $30.5 million.
- Its Research & Development has fluctuated over the past 5 years, first fell by 5.48% in 2022, then skyrocketed by 153.10% in 2024.
- Ocular Therapeutix's Research & Development (Quarterly) stood at $12.6 million in 2021, then increased by 7.67% to $13.5 million in 2022, then rose by 19.58% to $16.2 million in 2023, then spiked by 153.10% to $41.0 million in 2024, then soared by 41.30% to $52.4 million in 2025.
- Its last three reported values are $52.4 million in Q3 2025, $51.1 million for Q2 2025, and $42.9 million during Q1 2025.